Categories: News

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT.

On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.

The webcast will be available for replay for 30 days following the presentation and can be accessed at www.Humacyte.com and https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&page=huma&url=https://wsw.com/webcast/oppenheimer9/huma/2712391.

About Humacyte
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Doug Blankenship
CFO, Humacyte
dblankenship@humacyte.com

Humacyte Media Contacts:
Juliana Blum
EVP, Commercial
blum@humacyte.com

Heather Anderson
handerson@6degreespr.com

Staff

Recent Posts

Nurse Practitioners Secure No. 1 Spot Across Three U.S. News & World Report Best Jobs Rankings

Profession Ranks #1 for Best Job, Best Health Care Job and Best STEM Job AUSTIN,…

2 hours ago

A Groundbreaking Forum at HIMSS25 Focused on Behavioral Health

LAS VEGAS, Jan. 15, 2025 /PRNewswire/ -- Informa Connect announces a landmark collaboration with Behavioral…

2 hours ago

Purina Awards $125,000 to Five U.S.-Based Pet Startups through 2025 Pet Care Innovation Prize

Winning startups across the pet industry – from veterinary care to treats and e-commerce –…

2 hours ago

Data Innovations Appoints New President and CEO, Eric Dingfelder

COLCHESTER, Vt., Jan. 15, 2025 /PRNewswire/ -- Leading lab middleware company Data Innovations, LLC, has…

2 hours ago

Accelerated Cure Project for MS and EMD Serono Partner to Provide Resources to Caregivers

WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Accelerated Cure Project (ACP) for Multiple Sclerosis (MS)…

2 hours ago